Impact of CYP2D6 inhibitors on tamoxifen metabolism in breast cancer patients

被引：0
|
作者：
Keller, Denise [1 ]
Medwid, Samantha [2 ]
Schwarz, Ute [2 ]
Legan, Robin [1 ]
Kim, Richard [2 ]
机构：
[1] London Hlth Sci Ctr, London, ON, Canada
[2] Univ Western Ontario, London, ON, Canada
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P0065
引用
收藏
页码：250 / 253
页数：4
相关论文
共 50 条
  • [21] Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene
    Novillo, A.
    Romero-Lorca, A.
    Gaibar, M.
    Rubio, M.
    Fernandez-Santander, A.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02): : 109 - 111
  • [22] Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene
    A Novillo
    A Romero-Lorca
    M Gaibar
    M Rubio
    A Fernández-Santander
    The Pharmacogenomics Journal, 2017, 17 : 109 - 111
  • [23] Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen Reply
    Dezentje, Vincent O.
    van Blijderveen, Nico J. C.
    Gelderblom, Hans
    Putter, Hein
    van Herk-Sukel, Myrthe P. P.
    Casparie, Mariel K.
    Egberts, Antoine C. G.
    Nortier, Johan W. R.
    Guchelaar, Henk-Jan
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : E586 - E586
  • [24] Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
    Fernandez-Santander, Ana
    Gaibar, Maria
    Novillo, Apolonia
    Romero-Lorca, Alicia
    Rubio, Margarita
    Chicharro, Luis Miguel
    Tejerina, Armando
    Bandres, Fernando
    PLOS ONE, 2013, 8 (07):
  • [25] CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
    He, Wei
    Grassmann, Felix
    Eriksson, Mikael
    Eliasson, Erik
    Margolin, Sara
    Thoren, Linda
    Hall, Per
    Czene, Kamila
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 548 - +
  • [26] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [27] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 176 - 180
  • [28] CYP2D6 GENOTYPING TO GUIDE USE OF TAMOXIFEN IN BREAST CANCER
    Irvin, William J., Jr.
    Weck, Karen E.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Chiu, Wing. K.
    Dees, E. Claire
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S88 - S88
  • [29] Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
    Charoenchokthavee, Wanaporn
    Panomvana, Duangchit
    Sriuranpong, Virote
    Areepium, Nutthada
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 149 - 155
  • [30] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
12345